Genetic polymorphisms associated with nigrostriatal dopaminergic depletion as measured with [I123]-FP-CIT SPECT in Parkinson’s disease
Objective: To conduct a genome-wide association study (GWAS) of striatal [I123]-FP-CIT SPECT signal as endophenotype to explore possible associations between genetic background and nigrostriatal dopaminergic…An in-vivo study of the integrity of the nigrostriatal pathways in drug-naive Parkinson’s disease patients using [11C]PE2I PET and neuromelanin-Magnetic Resonance Imaging
Objective: This study evaluated the relationship between the neurodegeneration of the substantia nigra neurons, assessed using Neuromelanin-sensitive MRI, and of the loss of striatal dopaminergic…Insular dopamine deficits in prodromal α-synucleinopathies
Objective: aim of the study was to evaluate the dopamine binding characterizing subjects both at prodromal and symptomatic stages in α-synucleinopathies, by means of ROI-based…Education and the motor effects of dopamine loss in Parkinson’s disease
Objective: To examine the relation between education and dopamine signal loss in PD. Background: In support of the cognitive reserve concept, it has consistently been…Artificial intelligence for the improvement of imaging biomarkers in Parkinson’s disease
Objective: To systematically review the current literature on the application of artificial intelligence (AI) for imaging biomarkers in Parkinson's disease (PD) and to identify translational…Network attack tolerance: A resilience proxy for Parkinson’s disease?
Objective: To investigate if individual capacity in network attack tolerance moderates the relationship between striatal dopamine loss and symptom severity in PD. Background: It was…Diabetes impact on nigrostriatal vulnerability in Parkinson’s Disease
Objective: aim of the study was to investigate whether diabetes mellitus influences nigrostriatal dopaminergic vulnerability in drug-naïve patients with early-stage Parkinson’s Disease (PD). Background: recently,…A 20-Year Follow-Up Case Report with Three DaT-SPECT Scans in Parkinson’s Disease Diagnosis
Objective: To describe a patient who underwent multiple DAT-SPECT scans over a 20-year clinical follow-up period in three distinct clinical settings: a normal scan excluding…DaTscan striatal binding ratio dynamics in mutations carriers at risk for Parkinson’s disease: A 2-year prospective study
Objective: To investigate the temporal dynamics of striatal binding ratios (SBRs) among individuals with Parkinson's disease (PD)-related mutations and its' association with likelihood ratio (LR)…Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA
Objective: Evaluate dopaminergic imaging DAT-SPECT as an enrichment strategy to avoid inclusion of participants with scans without evidence of dopaminergic deficit (SWEDD) in a Phase…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 15
- Next Page »